Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-06-28
2011-06-28
Belyavskyi, Michail (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07968304
ABSTRACT:
The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual.
REFERENCES:
patent: 4551435 (1985-11-01), Liberti et al.
patent: 4643718 (1987-02-01), Marten
patent: 6048529 (2000-04-01), Atassi et al.
patent: 6667158 (2003-12-01), Bavari et al.
patent: 6676622 (2004-01-01), Strahilevitz
patent: 7341843 (2008-03-01), Atassi
patent: 7691587 (2010-04-01), Atassi
patent: 2002/0019278 (2002-02-01), Yuan
patent: 2002/0155114 (2002-10-01), Marks et al.
patent: 2002/0197278 (2002-12-01), Allison
patent: 2004/0101534 (2004-05-01), Diamond
patent: 2004/0110284 (2004-06-01), Bavari et al.
patent: 2004/0175385 (2004-09-01), Marks et al.
patent: 2004/0265935 (2004-12-01), Atassi
patent: 2005/0106182 (2005-05-01), Li et al.
patent: 2007/0280965 (2007-12-01), Atassi
patent: 2007/0280966 (2007-12-01), Atassi
patent: 2008/0213255 (2008-09-01), Atassi
patent: 94/21684 (1994-09-01), None
patent: 2005/014798 (2005-02-01), None
patent: 2005/030119 (2005-04-01), None
patent: 2006/042149 (2006-04-01), None
Amersdorfer et al., “Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries,”Vaccine20:1640-1648 (2002).
Amersdorfer et al., “Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries,”Infect. Immun. 65:3743-3752 (1997).
Aoki, “Pharmacology and immunology of botulinum toxin serotypes,”J. Neurol. 248 Suppl. 1:3-10 (2001).
Atassi and Dolimbek, “Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A,”ProteinJ. 23:39-52 (2004).
Atassi and Oshima, “Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins,”Crit. Revs. Immunol. 19:219-260 (1999).
Atassi and Smith, “A proposal for the nomenclature of antigenic sites in peptides and proteins,”Immunochemistry15:609-610 (1978).
Dressler et al, “Mouse Diaphragm Assay for Detection of Antibodies Against Botulinum Toxin Type B”, Movement Disorders, vol. 20, No. 12, 1617-1619, 2005.
Dressler et al, “Botulinum toxin type B de novo therapy of cervical dystonia Frequency of antibody induced therapy failure”, J Neurol 252: 904-907, 2005.
Kozaki et al., “Development of antitoxin with each of two complementary fragments ofClostridium botulinumtype B derivative toxin,”Infection and Immunity18:761-766 (1977).
Kozaki et al., “Immunological characterization of Papain-induced fragments ofClostridium botulinumtype A neurotoxin and interaction of the fragments with brain synaptosomes,”Infection and Immunity57:2634-2639 (1989).
Kozaki et al., “The use of monoclonal antibodies to analyze the structure ofClostridium botulinumtype E derivative toxin,”Infection and Immunity52:786-791 (1986).
Krieglstein, Kerstin G. et al, Journal of protein Chemistry, vol. 13(1), pp. 49-57, 1994.
Kubota et al., “Epitope regions in the heavy chain ofClostridium botulinumtype E neurotoxin recognized by monoclonal antibodies,”Applied&Environmental Microbiol. 63:1214-1218 (1997).
Lacy et al., “Crystal structure of botulinum neurotoxin type A and implications for toxicity,”Nat. Struct. Biol. 5:898-902 (1996).
Lacy, D. B. et al, “Sequence homology and structural analysis of the Clostridial neurotoxins”, Journal of Molecular Biology, vol. 291, 1999, pp. 1091-1104.
LaPenotiere et al., “Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen,”Toxicon33:1383-1386 (1995).
Lebeda, Frank J. et al, “Predicting Differential antigen-antibody contact regions based on solvent accessibility”, Journal of Protein Chemistry, vol. 16(6), 1997, pp. 607-618.
Atassi et al., “Cross-reaction of mouse antibodies against Tetanus neurotoxin with Botulinum neurotoxins A and B,”International Conference 2002, Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Hannover, Germany, June 8-12, Abstract R12 (2002).
Atassi et al., “Localization and synthesis of the hormone-binding regions of the human thyrotropin receptor,”Proc. Natl. Acad. Sci. USA88:3613-3617 (1991).
Atassi et al., “Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with anti-toxin antibodies from three host species,”J. Prot. Chem. 15:691-700 (1996).
Atassi, “Immune recognition and cross-reactivity of botulinum neurotoxins,” inScientific and Therapeutic Aspects of Botulinum Toxins(edited by Brin et al.), pp. 385-408, Lippincott Williams and Wilkins, Philadelphia, PA (2002).
Bavari et al., “Identifying the principal protective antigenic determinants of type A botulinum neurotoxin,”Vaccine16:1850-1856 (1998).
Beecher, DJ et al, J. Protein Chemistry, vol. 16(7), pp. 701-712, 1997.
Byrne, MP et al, vol. 82, 2000, “Development of vaccines for prevention of botulism”, pp. 955-966.
Cenci Di Bello et al., “Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light-chain epitopes,”Eur. J. Biochem. 219:161-169 (1994).
Chen et al., “Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms,”Infect. Immun. 65:1626-1630 (1997).
Clayton and Middlebrook, “Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A,”Vaccine18:1855-1862 (2000).
Clayton et al., “Protective vaccination with a recombinant fragment ofClostridium botulinumneurotoxin serotype A expressed from a synthetic gene inEscherichia coli,” Infect. Immun. 63:2738-2742 (1995).
Dertzbaugh and West, “Mapping of protective and cross-reactive domains of the type A neurotoxin ofClostridium botulinum,” Vaccine14:1538-1544 (1996).
Dineen et al, Swiss Prot sequence Q8KHn9, Oct. 1, 2002.
Dolimbek and Atassi, “Protection against alpha-bungarotoxin poisoning by immunization with synthetic toxin peptides,”Mol. Immunol. 33:681-689 (1996).
Dolimbek, BZ et al, Molecular Immunology, vol. 44, pp. 1029-1041, 2007.
Dressler et al., “Antibody-induced botulinum toxin therapy failure: Can it be overcome by increased botulinum toxin doses?”Eur. Neurol. 47:118-121 (2002).
Gibson et al, Swiss Prot Accession No. Q97TT9, Oct. 1, 2001.
Goschel et al., “Botulinum A toxin therapy: Neutralizing and nonneutralizing antibodies—therapeutic consequences,”Exp. Neurol. 147:96-102 (1997).
Hambleton et al., “A possible common antigen on clostridial toxins detected by monoclonal anti-botulinum neurotoxin antibodies,” 449-450 (1984).
Hanna, Philip A. MD, Neurology, vol. 50(6), pp. 1624-1629, Jun. 1998.
Jankovic, Botulinum Toxin: Clinical Implications of Antigenicity and Immunoresistancey, in Brin et al. eds.,Scientific and Therapeutic Aspects of Botulinum Toxin, pp. 409-415, Lippincott Williams & Wilkins, Philadelphia, PA (2002).
Jankovic, Joseph MD et al, Neurology, vol. 45(9), pp. 1743-1746, Sep. 1995.
Kikuyama eta al, Swiss Prot sequence Q9PRU1, May 1, 2000.
Klein, “Complications and adverse reactions with the use of botulinum toxin,”Dis. Mon. 48:336-356 (2002).
Middlebrook, “Protection strategies against botulinum toxin,” in Atassi and Bixler (Eds.),Immunology of Poreteins and Peptides VIIIp. 93-98 Plunum Pres
Abel Kenton
Allergan Inc.
Baylor College of Medicine
Belyavskyi Michail
Condino Debra
LandOfFree
Determining and reducing immunoresistance to a botulinum... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Determining and reducing immunoresistance to a botulinum..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Determining and reducing immunoresistance to a botulinum... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2661064